Organization (Academic)
University of Shizuoka
ClinicalTrials.gov lists University of Shizuoka as lead sponsor of 11 trials. It has 1 active development program and 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Univerin, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers University of Shizuoka: 11 lead-sponsored trials and 1 legal-entity registration.
Disease areas (7)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Kidney Failure, Chronic | 4 |
| Renal Insufficiency, Chronic | 4 |
| Atherosclerosis | 3 |
| Malnutrition | 2 |
| Cognitive Dysfunction | 1 |
Showing 5 of 7 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2012 | 1 |
| 2011 | 1 |
| 2010 | 1 |
| 2008 | 1 |
| 2007 | 1 |
| 2005 | 1 |
| 2004 | 2 |
| 2001 | 1 |
| 2000 | 1 |
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| MF-1 | Parkinson Disease | Phase 1 | 1 |
Approved assets (1)
| Drug | Trials |
|---|---|
| CoEnzyme Q10 | 1 |
Journals published in (1)
| Journal | Publications |
|---|---|
| PloS one | 1 |
Latest dated events (11)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2012-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2011-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2010-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2008-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 11 events.
Biomarkers this organization publishes on (11)
Shown in this order: most publications first.
Showing 5 of 11 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarker capability evidence.